Table 1.
Characteristics of the study group according to availability of five observations
| eGFR observations |
||||
|---|---|---|---|---|
| All |
≥5 |
<5 |
P value |
|
| Characteristic |
N = 364 |
N = 257 |
N = 107 |
— |
| Women | 178 (48.9) | 128 (49.8) | 50 (46.7) | 0.59 |
| At the time of earliest eGFR observation | ||||
| Age (years) | 33 (27, 40) | 34 (28, 40) | 32 (26, 40) | 0.42 |
| Diabetes duration (years) | 19 (15, 26) | 19 (16, 26) | 18 (14, 24) | 0.047 |
| Age of diabetes onset (years) | 12 (8, 17) | 12 (7, 17) | 12 (8, 17) | 0.50 |
| ACR (mg/g) | 1,262 (526, 2,500) | 1,299 (559, 2,500) | 966 (471, 2,500) | 0.18 |
| HbA1c (%) | 9.5 (8.4, 10.8) | 9.5 (8.4, 10.8) | 9.6 (8.3, 11.0) | 0.98 |
| HbA1c (mmol/mol) | 80.3 (68.3, 94.5) | 80.3 (68.3, 94.5) | 81.4 (67.2, 96.7) | |
| eGFR (mL/min/1.73 m2) | 73 (57, 97) | 71 (56, 87) | 84 (63, 109) | 0.001 |
| Recorded at the research enrollment examination | ||||
| Systolic blood pressure (mmHg) | 134 (125, 148) | 135 (127, 150) | 134 (120, 144) | 0.21 |
| Diastolic blood pressure (mmHg) | 80 (74, 88) | 80 (74, 86) | 82 (78, 88) | 0.16 |
| Treatment with ACE-I or ARB | 241 (66.2) | 169 (65.8) | 72 (67.3) | 0.78 |
| Smoking | ||||
| Current | 75 (20.6) | 54 (21.0) | 21 (19.6) | 0.77 |
| Past | 111 (30.5) | 74 (28.8) | 37 (34.6) | 0.21 |
| Follow-up | ||||
| Follow-up duration (years) | 6.6 (4.2, 9.9) | 6.7 (4.4, 9.8) | 6.1 (3.7, 10.5) | 0.22 |
| eGFR measurements | 10 (4, 18) | 15 (9, 24) | 3 (2, 4) | |
| eGFR measurements per year | 1.7 (0.6, 3.4) | 2.7 (1.3, 3.9) | 0.5 (0.3, 0.8) | |
| Death at ESRD onset | 63 (17.3) | 48 (18.7) | 15 (14.0) | 0.28 |
| Preemptive kidney transplant | 17 (4.7) | 13 (5.1) | 4 (3.7) | 0.59 |
Data are presented as n (%) or median (1st, 3rd quartile).
P value for comparison between patients with <5 and ≥5 eGFR observations.